Scott T.  Reents net worth and biography

Scott Reents Biography and Net Worth

CFO of AbbVie

Scott Reents is Executive Vice President, Chief Financial Officer, responsible for global financial and business technology operations of the company. He previously served as Vice President, Tax and Treasury.

Mr. Reents joined Abbott in 2008 and held various leadership positions in the company, ultimately serving as Division Vice President, Corporate Tax. After AbbVie’s separation from Abbott in 2013, Mr. Reents led the tax function as Vice President, Tax.

Prior to joining Abbott, Mr. Reents worked in the finance organizations of Pfizer and Pharmacia and began his career at Deloitte.

He earned a bachelor’s degree in finance and economics from the University of Nebraska as well as a Juris Doctor and Master of Business Administration from Washington University.

What is Scott T. Reents' net worth?

The estimated net worth of Scott T. Reents is at least $4.56 million as of February 23rd, 2024. Mr. Reents owns 27,065 shares of AbbVie stock worth more than $4,562,888 as of June 15th. This net worth approximation does not reflect any other assets that Mr. Reents may own. Additionally, Mr. Reents receives an annual salary of $3,130,000.00 as CFO at AbbVie. Learn More about Scott T. Reents' net worth.

How old is Scott T. Reents?

Mr. Reents is currently 56 years old. There are 7 older executives and no younger executives at AbbVie. The oldest executive at AbbVie is Mr. Richard A. Gonzalez, Chairman & CEO, who is 70 years old. Learn More on Scott T. Reents' age.

What is Scott T. Reents' salary?

As the CFO of AbbVie Inc., Mr. Reents earns $3,130,000.00 per year. There are 4 executives that earn more than Mr. Reents. The highest earning executive at AbbVie is Mr. Richard A. Gonzalez, Chairman & CEO, who commands a salary of $7,190,000.00 per year. Learn More on Scott T. Reents' salary.

How do I contact Scott T. Reents?

The corporate mailing address for Mr. Reents and other AbbVie executives is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. AbbVie can also be reached via phone at (847) 932-7900. Learn More on Scott T. Reents' contact information.

Has Scott T. Reents been buying or selling shares of AbbVie?

Scott T. Reents has not been actively trading shares of AbbVie in the last ninety days. Most recently, Scott T. Reents sold 14,140 shares of the business's stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $177.44, for a transaction totalling $2,509,001.60. Following the completion of the sale, the chief financial officer now directly owns 27,065 shares of the company's stock, valued at $4,802,413.60. Learn More on Scott T. Reents' trading history.

Who are AbbVie's active insiders?

AbbVie's insider roster includes Carlos Alban (Vice Chairman), Roxanne Austin (Director), Kevin Buckbee (SVP), Nicholas Donoghoe (SVP), Brian Durkin (VP), Richard Gonzalez (CEO), Henry Gosebruch (EVP), Robert Michael (Vice Chairman), Scott Reents (Sr. VP & CFO ), Scott Reents (CFO), Timothy Richmond (EVP), Azita Saleki-Gerhardt (EVP), Laura Schumacher (Vice Chairman), Michael Severino (Vice Chairman), Perry Siatis (EVP), Elaine Sorg (SVP), Jeffrey Stewart (EVP), and Carrie Strom (SVP). Learn More on AbbVie's active insiders.

Are insiders buying or selling shares of AbbVie?

During the last year, insiders at the sold shares 11 times. They sold a total of 404,736 shares worth more than $70,989,822.24. The most recent insider tranaction occured on March, 20th when EVP Nicholas Donoghoe sold 21,082 shares worth more than $3,716,756.60. Insiders at AbbVie own 0.3% of the company. Learn More about insider trades at AbbVie.

Information on this page was last updated on 3/20/2024.

Scott T. Reents Insider Trading History at AbbVie

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/23/2024Sell14,140$177.44$2,509,001.6027,065View SEC Filing Icon  
3/1/2023Sell15,942$153.08$2,440,401.36809View SEC Filing Icon  
See Full Table

Scott T. Reents Buying and Selling Activity at AbbVie

This chart shows Scott T Reents's buying and selling at AbbVie by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

AbbVie Company Overview

AbbVie logo
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Read More

Today's Range

Now: $168.59
Low: $166.00
High: $169.24

50 Day Range

MA: $163.56
Low: $154.86
High: $170.43

2 Week Range

Now: $168.59
Low: $130.96
High: $182.89

Volume

3,933,662 shs

Average Volume

5,477,690 shs

Market Capitalization

$297.71 billion

P/E Ratio

50.03

Dividend Yield

3.73%

Beta

0.6